Back to Search
Start Over
AVB500, a receptor tyrosine kinase AXL inhibitor, has improved therapeutic efficacy in combination with bevacizumab compared to bevacizumab alone in uterine serous cancer mouse model
- Source :
- Gynecologic Oncology. 159:77
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
Details
- ISSN :
- 00908258
- Volume :
- 159
- Database :
- OpenAIRE
- Journal :
- Gynecologic Oncology
- Accession number :
- edsair.doi...........7bbf1186c03065e2b752e9bec8cac632
- Full Text :
- https://doi.org/10.1016/j.ygyno.2020.06.162